Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/17/2025

Creutzfeldt-Jakob Disease Diagnosis and Management

Clinical Presentation

  • Creutzfeldt-Jakob disease (CJD) should be considered in patients with rapidly progressive dementia (weeks to months), characterized by myoclonus, ataxia, pyramidal and extrapyramidal signs, and cognitive deficits, with a median survival of 5 months for typical CJD, as recommended by the American Academy of Neurology and the European Federation of Neurological Societies 1
  • Atypical CJD presentations may have slower progression, up to 11 months, and may include language disturbances, personality changes, and visual disturbances, including hallucinations, according to the American Academy of Neurology and the European Federation of Neurological Societies 1

Diagnostic Testing

  • MRI with DWI and FLAIR sequences is recommended to show hyperintensities in cortical regions, basal ganglia, and thalamic hyperintensities, and restricted diffusion in caudate nucleus and putamen, with a high sensitivity and specificity for CJD diagnosis, as stated by the American College of Radiology 1, 2
  • CSF testing for RT-QuIC, 14-3-3 protein, and t-Tau is recommended, with RT-QuIC having a high specificity (near 100%) and sensitivity (73-97%) for CJD diagnosis, according to the American Academy of Neurology 1
  • EEG may show characteristic patterns, including periodic sharp wave complexes, triphasic complexes, and continuous focal epileptiform patterns, which can support CJD diagnosis, as reported by the American Academy of Neurology 1
  • The diagnostic workup for Creutzfeldt-Jakob disease includes MRI with DWI and FLAIR sequences showing cortical ribboning and basal ganglia/thalamic hyperintensities, as well as CSF 14-3-3 protein and elevated total Tau protein, according to The Lancet Neurology guidelines 1

Epidemiology and Genetics

  • The incidence of CJD is approximately 1-2 cases per million annually, with a peak age of 55-75 years, and is associated with mutations in the PRNP gene, including codon 129 polymorphism, which influences disease phenotype and progression, as reported by The Lancet Neurology 1, 3
  • Family history may be present in genetic forms of CJD, and PRNP gene sequencing can help distinguish sporadic from genetic forms, according to the American Academy of Neurology 1
  • CJD belongs to a group of disorders called Transmissible Spongiform Encephalopathies (TSEs), caused by abnormal prion proteins that are highly resistant to standard sterilization procedures, as stated in Anaesthesia and The Lancet Neurology 1, 3

Infection Control and Prevention

  • Healthcare facilities must implement specific infection control measures, including proper instrument sterilization, destruction of contaminated instruments that contact high-risk tissues, use of single-use equipment when appropriate, and minimizing blood product transfusions, as recommended by the Centers for Disease Control and Prevention 1, 3
  • Standard infection control precautions should be implemented for all patients, and any instrument that contacts brain, spinal cord, or dura should be destroyed, as stated in Anaesthesia 3
  • Quarantine or destruction of instruments used on known or suspected CJD cases, and maintenance of tracking systems for all reusable equipment, are essential for preventing transmission, as recommended by the World Health Organization 1, 3

Treatment and Management

  • Since there is no curative therapy for CJD, treatment focuses on symptomatic and palliative care, including management of myoklonus, psychiatric symptoms, and pain, as stated by the European Association for Palliative Care 1
  • Symptom management, including myoclonus treatment with clonazepam, valproate, or levetiracetam, psychiatric symptom management with antipsychotics and anxiolytics, and pain management, is focused on improving patient quality of life, as recommended by the Infectious Diseases Society of America and European Federation of Neurological Societies 4, 1
  • End-of-life care, including palliative care consultation, hospice referral, and anticipatory medications for terminal symptoms, is essential for CJD patients, as indicated by the European Association for Palliative Care 1

Prognosis

  • CJD is a universally fatal disease, with a median survival time of 5 months after symptom onset, and most patients dying within one year of diagnosis, as stated by the National Institute of Neurological Disorders and Stroke 1